Shilpa Medicare has announced it has signed a new long-term development and commercial manufacturing agreement with NXI Therapeutics AG.
Under the agreement, Shilpa will provide comprehensive CMC development, process scale-up, GMP clinical supply and commercial manufacturing support spanning early development through commercialisation.
This is the third named partnership deal Shilpa has announced in the past year, as the CDMO continues to expand rapidly amid strengthening demand from Western biotechs for its integrated R&D capabilities and advanced GMP manufacturing.
The autoimmune and immune-modulation segments are among the fastest-growing therapeutic categories globally, driven by the increasing prevalence and demand for targeted immunotherapies.
While financial terms remain confidential, Shilpa stated the agreement includes potential for milestone-linked expansion and may evolve into a multi-year commercial supply relationship, subject to successful clinical and regulatory progression.
Mr Vishnukanth Bhutada, Managing Director, Shilpa Medicare Limited, said: "This collaboration reinforces Shilpa's transformation into a strategic innovation partner for global biotech companies."
"Our integrated development and commercial manufacturing capabilities enable us to support complex assets across the full product lifecycle."
We continue to see strong momentum in high-value biologics and speciality therapeutics, strengthening long-term growth visibility for our CDMO platform.
Dr Ruben Herrendorff, CEO, NXI Therapeutics AG, added: "Shilpa's scientific depth, quality systems and scalable GMP manufacturing capabilities make them an ideal partner as we advance our immunomodulatory programme toward clinical and commercial milestones."